Skip to main content
Levodopa and Carbidopa Tablets IP 100 mg + 25 mg Manufacturer

Levodopa and Carbidopa Tablets IP 100 mg + 25 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Levodopa and Carbidopa Tablets IP 100 mg + 25 mg Manufacturer product packaging

Levodopa and Carbidopa Tablets IP 100 mg + 25 mg | Manufacturer

Product image for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg Manufacturer; contract manufacturing, oem & quality control.

Product Information

Generic NameLevodopa and Carbidopa
ManufacturerHealthy Life Pharma Pvt. Ltd.
HSN Code30049099
PharmacopoeiaIP
Product TypeTablet
CategoryAntiparkinsonian drugs
SubcategoryAntiparkinsonian drugs
Active IngredientLevodopa and Carbidopa
Strength100 mg + 25 mg
Dosage FormTablet
Pack Size10 x 10 Tablets / Box (Alu-Alu / Blister)
Route of AdministrationOral
Prescription RequiredYes
Therapeutic CategoryAntiparkinsonian drugs

Medicine Details & Safety

Short DescriptionHealthy Life Pharma invites contract and third-party manufacturing enquiries for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.
Approved Uses / Indications1. Management of generalized tonic-clonic, focal, and absence epileptic seizures. 2. Adjunctive treatment in trigeminal neuralgia, neuropathic pain, and mood stabilization.
Full Description

Healthy Life Pharma invites contract and third-party manufacturing enquiries for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements.

Product technical specifications

Generic nameLevodopa and Carbidopa
CompositionLevodopa and Carbidopa
Strength100 mg + 25 mg
CategoryAntiparkinsonian drugs
PharmacopoeiaIP
Dosage formTablet

Product technical specifications

Generic nameAcarbose
CompositionAcarbose
Strength25 mg
CategoryAntidiabetic Drugs
PharmacopoeiaUSP / IP
Dosage formTablet

Manufacturing capabilities and infrastructure

For Levodopa and Carbidopa Tablets IP 100 mg + 25 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.

Quality control and assurance

Request the approved finished-product specification for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.

Primary and secondary packaging

The catalogue pack for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.

Contract manufacturing and private label

Submit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution.
Dosage InstructionsAdminister orally at regular scheduled intervals daily. Swallow whole with water; maintain consistent dosing to achieve stable therapeutic anticonvulsant plasma concentrations.
Side EffectsCommon: Drowsiness, fatigue, ataxia, dizziness, diplopia, nausea. Uncommon: Tremor, cognitive slowing, skin rash, mild transaminase elevation. Rare: Stevens-Johnson syndrome, hepatotoxicity, pancreatitis, aplastic anemia.
Warnings and PrecautionsAbrupt Discontinuation: Never stop abruptly; gradual withdrawal over weeks is required to avoid precipitating status epilepticus. Suicidal Ideation: Monitor closely for emergence of depressive mood changes or suicidal thoughts. Hepatic & Hematologic Testing: Regular blood counts and liver enzymes are recommended.
Contraindications1. Known hypersensitivity to Levodopa and Carbidopa or related anticonvulsant chemical structures.
2. Acute intermittent porphyria or atrioventricular conduction block.
3. Severe hepatic impairment or preexisting bone marrow depression.
Drug Interactions1. Other Antiepileptics (Phenytoin, Carbamazepine, Valproate): Mutual metabolic induction or inhibition requiring serum monitoring.
2. Oral Contraceptives: Enzyme-inducing anticonvulsants decrease contraceptive hormone efficacy.
3. CNS Depressants & Alcohol: Marked intensification of central nervous system depression.

Frequently Asked Questions

QuestionAnswer
Can I request third-party manufacturing for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg?Submit your brand, quantity and packaging requirements for manufacturing feasibility review.
Which pharmacopoeial standard applies for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg?The source specification is IP; confirm the required standard before contracting.
What quality tests are applicable for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg?Request the approved finished-product specification and batch testing plan.
Can packaging be customized for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg?Submit artwork and pack requirements for technical and regulatory review.
How do I request a manufacturing quotation for Levodopa and Carbidopa Tablets IP 100 mg + 25 mg?Provide forecast volume, target market, strength and packaging requirements.

Product Hashtags

#Levodopa#Manufacturer#PharmaB2B

Related Products

Latest Posts